Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus
- 1 September 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 20 (9) , 975-988
- https://doi.org/10.1089/hum.2009.028
Abstract
Oncolytic adenoviruses are anticancer agents that replicate within tumors and spread to uninfected tumor cells, amplifying the anticancer effect of initial transduction. We tested whether coating the viral particle with polyethylene glycol (PEG) could reduce transduction of hepatocytes and hepatotoxicity after systemic (intravenous) administration of oncolytic adenovirus serotype 5 (Ad5). Conjugating Ad5 with high molecular weight 20-kDa PEG but not with 5-kDa PEG reduced hepatocyte transduction and hepatotoxicity after intravenous injection. PEGylation with 20-kDa PEG was as efficient at detargeting adenovirus from Kupffer cells and hepatocytes as virus predosing and warfarin. Bioluminescence imaging of virus distribution in two xenograft tumor models in nude mice demonstrated that PEGylation with 20-kDa PEG reduced liver infection 19- to 90-fold. Tumor transduction levels were similar for vectors PEGylated with 20-kDa PEG and unPEGylated vectors. Anticancer efficacy after a single intravenous injection was retained at the level of unmodified vector in large established prostate carcinoma xenografts, resulting in complete elimination of tumors in all animals and long-term tumor-free survival. Anticancer efficacy after a single intravenous injection was increased in large established hepatocellular carcinoma xenografts, resulting in significant prolongation of survival as compared with unmodified vector. The increase in efficacy was comparable to that obtained with predosing and warfarin pretreatment, significantly extending the median of survival. Shielding adenovirus with 20-kDa PEG may be a useful approach to improve the therapeutic window of oncolytic adenovirus after systemic delivery to primary and metastatic tumor sites.Keywords
This publication has 63 references indexed in Scilit:
- Redundant and Synergistic Mechanisms Control the Sequestration of Blood-born Adenovirus in the LiverMolecular Therapy, 2009
- Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian HamstersJournal of Virology, 2009
- Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1Blood, 2009
- Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelProceedings of the National Academy of Sciences, 2008
- Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivoProceedings of the National Academy of Sciences, 2008
- Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Therapy, 2007
- Targeted Cancer Gene Therapy Using a Hypoxia Inducible Factor–Dependent Oncolytic Adenovirus Armed with Interleukin-4Cancer Research, 2007
- Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic AdenovirusMolecular Therapy, 2007
- Immune Gene–Viral Therapy with Triplex Efficacy Mediated by Oncolytic Adenovirus Carrying an Interferon-γ Gene Yields Efficient Antitumor Activity in Immunodeficient and Immunocompetent MiceMolecular Therapy, 2006
- The impact of adenovirus infection on the immunocompromised hostReviews in Medical Virology, 2003